Acasti pharma announces initiation of pharmacokinetic study for gtx-102, the company's drug candidate for the treatment of ataxia telangiectasia

Laval, quÉbec, sept. 13, 2022 (globe newswire) -- acasti pharma inc. (“acasti” or the “company”) (nasdaq: acst and tsx-v: acst), today announces the initiation of its planned pharmacokinetic (pk) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, gtx-102, compared to an intramuscular injection of betamethasone and to an oral solution of betamethasone, in 48 healthy subjects. the first subject, first dose was administered on september 13th. this pk study is the next step in the proposed 505(b)(2) regulatory pathway for gtx-102 and is expected to be completed with top line results reported before year end.
ACST Ratings Summary
ACST Quant Ranking